Tower Research Capital (TRC)’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-379
| Closed | -$3.26K | – | 6106 |
|
|
2024
Q1 | $3.26K | Sell |
379
-139
| -27% | -$664 | ﹤0.01% | 4896 |
|
|
2023
Q4 | $1.81K | Sell |
518
-2
| -0.4% | -$7 | ﹤0.01% | 5320 |
|
|
2023
Q3 | $1.85K | Sell |
520
-2
| -0.4% | -$11 | ﹤0.01% | 5258 |
|
|
2023
Q2 | $3.04K | Buy |
522
+355
| +213% | +$6.49K | ﹤0.01% | 5124 |
|
|
2023
Q1 | $6K | Sell |
167
-259
| -61% | -$8.49K | ﹤0.01% | 4908 |
|
|
2022
Q4 | $13K | Buy |
426
+84
| +25% | +$2.54K | ﹤0.01% | 3654 |
|
|
2022
Q3 | $11K | Buy |
342
+261
| +322% | +$9.96K | ﹤0.01% | 4483 |
|
|
2022
Q2 | $3K | Buy |
81
+68
| +523% | +$2.63K | ﹤0.01% | 5433 |
|
|
2022
Q1 | $1K | Buy |
+13
| New | +$654 | ﹤0.01% | 5903 |
|
|
2021
Q4 | – | Sell |
-22
| Closed | -$2K | – | 6701 |
|
|
2021
Q3 | $2K | Buy |
+22
| New | +$1.86K | ﹤0.01% | 5323 |
|
|
2021
Q2 | – | Sell |
-274
| Closed | -$45K | – | 5959 |
|
|
2021
Q1 | $45K | Sell |
274
-304
| -53% | -$58.5K | ﹤0.01% | 3224 |
|
|
2020
Q4 | $135K | Buy |
578
+467
| +421% | +$65K | ﹤0.01% | 2075 |
|
|
2020
Q3 | $12K | Buy |
+111
| New | +$5.94K | ﹤0.01% | 4042 |
|
|
2019
Q2 | – | Sell |
-13
| Closed | -$4K | – | 4445 |
|
|
2019
Q1 | $4K | Buy |
+13
| New | +$2.82K | ﹤0.01% | 3217 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4158 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 3970 |
|
|
2017
Q3 | – | Sell |
-11
| Closed | -$5K | – | 4226 |
|
|
2017
Q2 | $5K | Buy |
+11
| New | +$6.71K | ﹤0.01% | 2029 |
|
|
2017
Q1 | – | Sell |
-9
| Closed | -$9K | – | 4082 |
|
|
2016
Q4 | $9K | Buy |
9
+4
| +80% | +$4.57K | ﹤0.01% | 2733 |
|
|
2016
Q3 | $6K | Buy |
5
+2
| +67% | +$2.25K | ﹤0.01% | 2460 |
|
|
2016
Q2 | $2K | Sell |
3
-7
| -70% | -$9.28K | ﹤0.01% | 3989 |
|
|
2016
Q1 | $14K | Buy |
+10
| New | +$14.2K | ﹤0.01% | 1648 |
|
|
2015
Q4 | – | Sell |
-7
| Closed | -$13K | – | 5171 |
|
|
2015
Q3 | $13K | Buy |
7
+6
| +600% | +$14K | ﹤0.01% | 2113 |
|
|
2015
Q2 | $1K | Sell |
1
-7
| -88% | -$16.4K | ﹤0.01% | 4108 |
|
|
2015
Q1 | $23K | Buy |
+8
| New | +$21K | ﹤0.01% | 2149 |
|
Other funds holding TCON
Tower Research Capital (TRC)'s TCON Position: Q2 2024 in Review
Tower Research Capital (TRC) sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 379 shares — an estimated $3.26K sold.
Tower Research Capital (TRC) first reported a position in TCON in Q1 2015 and held it in 22 quarters. The position peaked at $135K in Q4 2020. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Tower Research Capital (TRC) reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 379 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $3.26K.
- Tower Research Capital (TRC) first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 22 quarters.
- Tower Research Capital (TRC)'s TRACON Pharmaceuticals, Inc. Common Stock position peaked at $135K in Q4 2020.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.